{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-010013","form_type":"8-K","ticker":"PRPH","cik":"0000868278","company_name":"ProPhase Labs, Inc.","filed_at":"2024-03-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.091792+00:00","generated_at":"2026-06-04T18:25:11.158172+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ProPhase Labs reports FY 2023 net loss of $16.8M; revenue down 63% to $45.2M","bullets":["Net loss of $16.8M ($0.98 per share) vs. net income of $18.5M ($1.17 per share) in FY 2022.","Revenue fell 63% to $45.2M due to COVID-19 testing decline; diagnostic services revenue dropped $83.5M.","Nebula Genomics signed international B2B deal with MenaDNA; potential $10-20M annual revenue from another agreement.","Pharmaloz capacity guidance raised to $45M run-rate by Q3 2024, then $80-100M by H1 2025; existing customers accepted 15.2% price increase.","BE-Smart esophageal cancer test on track for H2 2024 commercialization; Equivir trial interim results showed 68% of respiratory incidents in placebo group."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-010013","json":"https://secwatch.observer/filing/0001493152-24-010013.json","markdown":"https://secwatch.observer/filing/0001493152-24-010013.md","text":"https://secwatch.observer/filing/0001493152-24-010013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/868278/000149315224010013/0001493152-24-010013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/868278/000149315224010013/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T18:25:11.158172+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8b0f51acab48b0d9e05894204225bcab87c3712d","claim":"ProPhase Labs, Inc. reported financial results for the full-year ended December 31, 2023.","evidence_excerpt":"On March 15, 2024, ProPhase Labs, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/868278/000149315224010013/0001493152-24-010013-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full-year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}